Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring <i>BRAF</i> Class 3 Mutations
<i>BRAF</i> class 3 mutations in NSCLC may identify a novel targetable population sensitive to EGFR-TKIs.
Authors
- Stefania Angelicola
- Maria Sofia Semprini (ORCID: https://orcid.org/0000-0001-5013-6908)
- Stefano Brocchi (ORCID: https://orcid.org/0000-0002-7563-8936)
- Francesco Gelsomino (ORCID: https://orcid.org/0000-0002-9204-1728)
- Elisa Gruppioni (ORCID: https://orcid.org/0000-0002-4334-6170)
- Mariateresa Frascino
- Andrea Ardizzoni (ORCID: https://orcid.org/0000-0003-2678-0714)
- Arianna Palladini (ORCID: https://orcid.org/0000-0001-6105-4895)
- Pier‐Luigi Lollini (ORCID: https://orcid.org/0000-0003-1702-4108)
- Francesca Ruzzi (ORCID: https://orcid.org/0000-0001-9555-3166)
- Hugo de Jonge (ORCID: https://orcid.org/0000-0003-2777-4084)
- Francesca Giunchi (ORCID: https://orcid.org/0000-0001-5298-939X)
- Alessandro Di Federico (ORCID: https://orcid.org/0000-0001-8877-4315)
- Barbara Melotti (ORCID: https://orcid.org/0000-0003-1041-391X)
- Francesca Sperandi (ORCID: https://orcid.org/0000-0002-1581-3456)
- Andrea De Giglio (ORCID: https://orcid.org/0000-0002-0731-5721)
- Annalisa Altimari (ORCID: https://orcid.org/0000-0001-9944-2455)
- Irene Siracusa
- Beatrice Bisanti
Institutions
- University of Pavia (IT)
- Azienda USL di Bologna (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Bologna (IT)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po.24.00240
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Ministero della Salute
- Università degli Studi di Parma
- National Cancer Institute